Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902329 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 195
- Enrollment target
NCT01902329: Completed Phase 1 study, sponsored by Seagen.
NCT01902329 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 195 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (225% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01902329, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 195 participants
- Enrollment target
Study Summary
This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a hypomethylating agent (HMA). The main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest dose that does not cause unacceptable side effects) of SGN-CD33A in patients with acute myeloid leukemia (AML). The MTD will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemia activity of SGN-CD33A will be assessed.
Interventions
- DRUG SGN-CD33A
- DRUG HMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-12-08 |
| Phase | Phase 1 |
What the finished NCT01902329 record still lists
NCT01902329 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (225% higher).
The record links to 0 conditions, and to 2 interventions - of which SGN-CD33A is the first listed.
NCT01902329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01902329 about?
NCT01902329 is a clinical study titled "A Safety Study of SGN-CD33A in AML Patients". This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a hypomethylating agent (HMA). The main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest dose that does not cause unacceptable s...
What is the current status of trial NCT01902329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 195 participants. The study started on 2013-07. Estimated completion is 2017-12-08.
What interventions are being tested in trial NCT01902329?
The interventions under investigation include: SGN-CD33A (DRUG), HMA (DRUG).
Who is sponsoring clinical trial NCT01902329?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01902329's enrollment target sits among peer trials
195 281st of 2000 higher than 1,719 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia